What Tyche does

Tyche Industries Limited is a publicly listed (BSE: 532384) pharmaceutical manufacturer founded in 1998 and headquartered in Hyderabad, India. The company manufactures Active Pharmaceutical Ingredients (APIs), Advanced and Chiral Intermediates, Glucosamine-based Nutraceuticals, and offers full-service Contract Development and Manufacturing Organization (CDMO) capabilities to global pharmaceutical clients. Its commercial portfolio spans 19 APIs across therapeutic categories including CNS (Sertraline, Fluoxetine, Donepezil), anti-emetic (Palonosetron), anti-retroviral (Tenofovir variants), anti-histamine (Cetirizine, Rupatadine), urology (Silodosin, Solifenacin, Tamsulosin), anti-microbial (Nitrofurantoin), and anti-arthritic (Glucosamine), with five additional APIs in development.

Manufacturing is concentrated at a single Kakinada, Andhra Pradesh facility comprising 7 production blocks across 28,844 square meters with 210,000 liters of reactor volume and 6 clean rooms. Reactor capacity spans 100L to 6,300L with operating temperatures from -30°C to 270°C, supporting a wide reaction portfolio including asymmetric synthesis, hydrogenation, Grignard, nitration, and chiral resolution. The company holds USFDA, PMDA (Japan), WHO GMP, and CDSCO certifications, and in September 2025 successfully cleared Brazil's ANVISA GMP inspection. R&D is conducted by PhD- and Masters-level chemists at a kilo- and pilot-plant-equipped center covering route development, IP evaluation, impurity characterization, and polymorphic studies.

Tyche generates revenue through direct B2B enterprise sales of catalog APIs to pharmaceutical companies, supported by multi-jurisdictional Drug Master File (USDMF, EUDMF, KDMF, JDMF, Canadian DMF) submissions and CEP-granted status, plus project-based CDMO revenue from custom synthesis, process development, and contract manufacturing with tech-transfer from client sites. Pricing is quote-based and negotiated per contract rather than transactionally listed. The company is led by Managing Director and Chairman G Sandeep and Executive Director G Ganesh Kumar, with a founder-family ownership structure evident from G-prefixed executive names and no disclosed private equity or venture capital sponsorship.

Name

Tyche

Legal name

Tyche Industries Limited

Website

http://www.tycheindustries.net

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

101–250 employees

Short description

Tyche Industries Limited is an Indian B2B manufacturer of Active Pharmaceutical Ingredients, Chiral Intermediates, Nutraceuticals, and CDMO services, selling to global pharmaceutical companies from a single Kakinada manufacturing facility under USFDA, PMDA, WHO, CDSCO, and ANVISA GMP certifications.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

Keywords

• Active pharmaceutical ingredients
• Pharmaceutical intermediates
• Contract manufacturing
• Nutraceutical ingredients
• Chiral chemistry

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredients (API) Sales: Manufacturing and sale of commercial APIs including Sertraline HCI, Fluoxetine, Racecadotril, Palonosetron HCI, Silodosin, Solifenacin Succinate, Tamsulosin HCI, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide Fumarate, Rupatadine Fumarate, Glucosamine variants, Nitrofurantoin variants, Donepezil HCI, and Cetirizine HCI to pharmaceutical companies.
2. CDMO Services: Contract Development and Manufacturing Organization services including Chemical Process Development, Drug Substance manufacture and Custom Synthesis, CMC & Regulatory Support, Analytical Development Services (Method Development, Validation, Impurity identification, Characterization, Reference standard characterization, Stability Studies), and Contract Manufacture of APIs & Starting Materials with tech-transfer from client sites.
3. Advanced and Chiral Intermediates: Manufacturing and supply of pharmaceutical intermediates used in API synthesis, including Sertraline intermediates, Tamsulosin intermediates, Raloxifene/Flavoxate intermediates, Solifenacin intermediates, Tenofovir intermediates, and Donepezil intermediates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Tyche Industries manufactures Active Pharmaceutical Ingredients (APIs), Advanced & Chiral Intermediates, and Glucosamine-based Nutraceuticals at its Kakinada facility, and provides CDMO services including chemical process development, custom synthesis, analytical development, CMC & regulatory support, and contract manufacturing of APIs and starting materials. The company serves global pharmaceutical companies across CNS, anti-emetic, anti-retroviral, anti-histamine, anti-arthritic, urological, anti-microbial, and anti-diarrheal therapeutic categories.

Product overview

Tyche Industries is a manufacturer of Active Pharmaceutical Ingredients (APIs), Advanced Intermediates, and Chiral Intermediates, headquartered in Hyderabad, India. The company's product portfolio consists of four core offerings: (1) Commercial and development-stage APIs covering multiple therapeutic categories; (2) Advanced and Chiral Intermediates used as pharmaceutical building blocks; (3) Glucosamine-based Nutraceuticals for joint health; and (4) CDMO services providing contract development and manufacturing for APIs and fine chemicals. The company also offers regulatory filing services including DMF and CEP submissions for international markets.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs) Commercial and development-stage Active Pharmaceutical Ingredients covering multiple therapeutic categories. Manufactured and supplied to global pharmaceutical companies for finished drug formulation, with regulatory filings (DMF, CEP) supporting client product approvals in US, EU, Japan, Korea, and other markets.
• Advanced & Chiral Intermediates

Quantifiable outcome

• Successfully completed ANVISA GMP inspection at Kakinada facility in September 2025

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Divi's Laboratories: India-headquartered API and intermediates manufacturer with strong CDMO operations, USFDA/EMA-approved facilities, and a global generic-API franchise. Closest direct peer to Tyche in scale, regulatory footprint, and contract services orientation.
• Laurus Labs: Indian API and CDMO company serving global generics and ARV markets, with comparable USFDA-inspected manufacturing and contract development capabilities. Highly comparable on customer base (anti-retrovirals, CNS) and CDMO growth thesis.
• Hikal: India-based manufacturer of APIs, intermediates, and fine chemicals with CDMO services and USFDA/EDQM certifications. Comparable on size, product mix (specialty small molecules), and B2B pharma customer base.
• Sai Life Sciences: Indian CDMO offering custom synthesis, process development, and API manufacturing for innovator and generic pharma. Comparable contract-services model and USFDA/EMA-grade quality systems.
• Granules India: Indian manufacturer of APIs, pharmaceutical intermediates, and finished dosages with global regulatory filings. Comparable customer base and product mix in commodity generics.
• Ipca Laboratories: Indian pharma company manufacturing APIs and formulations across therapeutic categories including anti-arthritic and anti-malarial, with USFDA-approved plants. Comparable API manufacturing capability and export focus.
• Natco Pharma: Indian pharma with API manufacturing for generics and niche molecules, including complex chemistries. Comparable customer profile in regulated-market generics.

Broad incumbents

• Aurobindo Pharma: Large Indian vertically-integrated pharma with substantial API manufacturing and global generics presence. Overlaps with Tyche on API capability but operates at much larger scale and across finished formulations.
• Dr. Reddy's Laboratories: Major Indian pharma with API and finished dosage operations serving global markets. Overlaps with Tyche on the API side but is significantly larger and more diversified.

Emerging players

• Sequent Scientific: India-based manufacturer of APIs and intermediates with regulatory certifications. Comparable manufacturing-services model though more focused on animal health adjacencies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tyche